NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
6 hedge funds and large institutions have $874K invested in NLS Pharmaceutics Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
1% less capital invested
Capital invested by funds: $886K → $874K (-$12K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$6.46K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$4.53K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$201 |
Top Sellers
NLSPW Hedge Fund Activity: Q2 2021 in Review
6 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2021, worth a combined $874K — down 1.4% from $886K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NLSPW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Bank Julius Baer & Co, opening a new position worth an estimated $6.46K.
- 6 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2021, up from 5 in Q1 2021.
- Funds reported $874K of NLS Pharmaceutics Warrant stock for Q2 2021, down 1.4% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q2 2021 and 0 closed out, a net change of +1 holder.
- The largest NLS Pharmaceutics Warrant buyer in Q2 2021 was Bank Julius Baer & Co, an estimated $6.46K added.
Based on aggregated 13F filings for Q2 2021.